İstanbul Medical Journal (May 2025)

The Role of MR-proADM in Determining COVID-19 Pneumonia and Clinical Severity

  • Sacit Akdeniz,
  • Yusuf Yürümez,
  • Hayrullah Yazar,
  • Necip Gökhan Güner,
  • Nuray Aslan,
  • Ensar Durmuş,
  • Fatih Güneysu

DOI
https://doi.org/10.4274/imj.galenos.2025.14194
Journal volume & issue
Vol. 26, no. 2
pp. 109 – 113

Abstract

Read online

Introduction: This study aimed to compare the success of mid-regional pro adrenomedullin (Mr-proADM) levels, in determining disease severity in coronavirus disease-2019 (COVID-19) patients with other inflammatory biomarkers and Pneumonia Severity Index (PSI) scores. Methods: This prospective, observational, analytical, cross-sectional study was conducted at Sakarya Training and Research Hospital, Department of Emergency Medicine. The 88 patients who presented with suspected COVID-19 and were diagnosed accordingly were included in the examination. The patients were organized into four groups based on reverse transcription polymerase chain reaction and chest computed tomography outcomes. Demographic data, presenting complaints, comorbidities, laboratory values, imaging modalities, PSI score, and pneumonia diagnosis data were documented for each patient. All data were examined with SPSS software, and a p<0.05 was considered statistically significant. Results: The patients’ mean age was 53 and 60% were female. Fatigue (58%) was the most typical complaint, and hypertension (39%) was the most prevalent comorbidity. When comparing the groups, it was observed that patients in group 4 exhibited a decrease in white blood cell counts and increased levels of C-reactive protein (CRP), ferritin, and D-dimer, which was statistically significant. Nevertheless, no significant distinction was seen in Mr-proADM levels among the groups. The comparison based on the PSI score determined that Mr-proADM levels were significantly raised in the high-risk group. Conclusion: Mr-proADM levels correlated with CRP, ferritin, and procalcitonin levels in predicting patients in the high-risk group based on the PSI score. Based on these determinations, Mr-proADM levels may also help predict clinical severity in the emergency department. Nevertheless, further studies incorporating larger datasets are needed to support these data.

Keywords